# A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02302716` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02302716](<https://clinicaltrials.gov/study/NCT02302716>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02302716

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 493 participants.

## Technical summary

Registry record NCT02302716. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-07 (actual). Results posted on 2017-10-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 493 participants (enrolled count; ClinicalTrials.gov record NCT02302716, source copy `cardio:ctgov-nct02302716-2017-10-24`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02302716, source copy `cardio:ctgov-nct02302716-2017-10-24`, retrieved 2026-10-26)
- Primary completion: 2016-07 (actual) (ClinicalTrials.gov record NCT02302716, source copy `cardio:ctgov-nct02302716-2017-10-24`, retrieved 2026-10-26)
- Completion: 2016-07 (actual) (ClinicalTrials.gov record NCT02302716, source copy `cardio:ctgov-nct02302716-2017-10-24`, retrieved 2026-10-26)
- Results first posted: 2017-10-24 (ClinicalTrials.gov record NCT02302716, source copy `cardio:ctgov-nct02302716-2017-10-24`, retrieved 2026-10-26)
- Countries: United States; India; Puerto Rico; Russia; South Korea; Taiwan; Türkiye (ClinicalTrials.gov record NCT02302716, source copy `cardio:ctgov-nct02302716-2017-10-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02302716-2017-10-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
- Acronym: ELEMENT 5
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): LY2963016
- Intervention (Drug): LANTUS®
- Intervention (Drug): Oral Antihyperglycemic Medication
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study (`cardio:pubmed-31119716`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 25d0bbebe3bc8e0b47d83d417b704f4403203bee3ae27f8ce8d4c315cd2b5429
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
